Professor Dominique Bremond-Gignac is the Head of Ophthalmology at University Hospital Necker-Enfants Malades of Paris Cité University in Paris, France. In this interview, we chatted with her about her experiences of combination treatment; in particular, with prescribing HOYA MiYOSMART spectacle lenses and atropine for children with myopia.
We talk to Dr May Zhang and Jeff Brown, leaders at HOYA Vision Care, about the importance of outdoor time and sun protection when it comes to managing children with myopia progression and how we can incorporate this into our clinical practice.
There’s a lot we already know about Essilor Stellest spectacle lenses for correcting and controlling myopia. This article explores recent published studies on visual fields, a crossover trial and the 3-year and 4-year clinical trial data.
With myopia controlling spectacles, parents may parents may express concern about the potential for accidental breakage when their children are playing sports. What are your recommendations? This case takes in various clinical, safety and functional aspects for kids wearing myopia control spectacle lenses.
The HOYA MiYOSMART was the first of the new generation of myopia control spectacle lenses, with evidence for slowing myopia progression by at least half. Learn more about efficacy, the lens design, visual outcomes and more.
This prospective observational study found that DIMS spectacle lenses, atropine 0.01% and the combination of the two all showed robust efficacy for myopia control in European children. The combination treatment showed slightly better refractive control than the mono-therapies, but axial length growth was similar in all treatment groups.
The first year data from the ongoing CYPRESS randomized clinical trial show that Diffusion Optics Technology (DOT) spectacle lenses can regulate contrast signals across the retina to reduce myopia progression in children aged 6-10 years, and are safe and effective to wear.
The SightGlass DOT 0.2 lens presents a new theory in myopia control, with clinical trial evidence of efficacy in children from 6 to 10 years of age. Diffusion Optics Technology (DOT) incorporates microdots to modulate retinal contrast; it does not employ defocus as for other optical treatments. Learn more here.
The contrast theory in myopia development and control is based on links between retinal cone expressions, genetics and myopia. This is distinct from peripheral defocus and simultaneous defocus theories and underpins the new SightGlass DOT 0.2 spectacle lens for myopia control. Learn more here.
A dose-response is where an increasing amount of a medication or intervention is correlated with a better clinical outcome. When it comes to myopia control, we investigate the evidence for a dose-response with spectacle, contact lens, atropine and outdoor time interventions.
